Acton Prolongatum injection uses in the following:

• Adrenal insufficiency (Addison's disease)

• Infantile spasms

• Multiple sclerosis (MS) exacerbations

• Nephrotic syndrome

• Rheumatoid arthritis

• Systemic lupus erythematosus (SLE) flares

• Eosinophilic conditions

• Wound healing and tissue repair

Acton prolongatum 60IU injection binds to specific receptors on the adrenal cortex, leading to an increase in the production and release of corticosteroid hormones, most notably cortisol. This increase in cortisol levels regulates various physiological processes, including metabolism, immune response, and stress response. In conditions like adrenal insufficiency (Addison's disease), where the adrenal glands fail to produce adequate cortisol, this therapy helps restore hormone balance, alleviating symptoms associated with cortisol deficiency and maintaining overall physiological stability.

• Corticosteroids (e.g., Prednisone) – Moderate
  May reduce the effectiveness of growth hormone therapy. Dose adjustment may be needed.

• Insulin or Oral Antidiabetics – Moderate
  Can affect blood sugar levels; monitoring is required to adjust doses and avoid hypo- or hyperglycemia.

• Thyroid Hormones (e.g., Levothyroxine) – Moderate
  Growth hormone may increase the requirement for thyroid hormone; thyroid function tests may be needed.

• Estrogen Therapy – Mild
  High-dose oral estrogens may reduce growth hormone effectiveness, particularly in children.

• Glucocorticoids (High-dose) – Severe
  May significantly counteract growth-promoting effects; concurrent use should be carefully monitored.

• Store at room temperature, between up to  20°C to 25°C

• Keep away from moisture, heat, and light.

• It should not be frozen.

• Keep away from children and pets.

Acton prolongatum 60IU injection (ACTH) medication can be administered through various routes, including intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) injection, and in some cases, intranasal spray or intradermal injection.. It is essential to follow the healthcare provider's instructions for the correct administration technique, dosage, and frequency to ensure safe and effective use of the medication.

Acton Prolongatum side effects, although not everyone will experience them. 

Serious

• Allergic reactions

• Adrenal suppression

• Osteoporosis

• Eye conditions

• Gastrointestinal issues

• Cardiovascular effects

• Metabolic effects

• Cushing's syndrome

Common

• Increased appetite

• Mood changes

• Fluid retention

• High blood pressure

• Increased blood glucose

• Insomnia

• Skin changes

1. Medical History & Medications: Inform your doctor about your complete medical history, allergies, current medications, upcoming surgeries, and vaccinations.

2. Dosage & Discontinuation: Do not adjust the dose or stop the injection abruptly; follow your healthcare provider’s guidance.

3. Monitoring Health: Regularly monitor infections, bone health, eye conditions (like glaucoma), and other hormonal changes.

4. Long-Term Use: Prolonged use may lead to corticosteroid dependence; discuss gradual dose reduction strategies with your doctor.

5. Hormonal Effects: Report any changes in menstrual cycle, libido, or other hormonal symptoms, and maintain open communication with your healthcare provider.

1. Gundgurthi, Abhay & Garg, M K & Dutta, M & Pakhetra, R., Intramuscular ACTH stimulation test for assessment of adrenal function. J Assoc Physicians India, 2013, 61, 320-4, https://www.researchgate.net/publication/260003252_Intramuscular_ACTH_stimulation_test_for_assessment_of_adrenal_function  [Accessed on 23 August 2023]
2. Duchowny MS, Chopra I, Niewoehner J, Wan GJ, Devine B, A systematic literature review and indirect treatment comparison of efficacy of repository Corticotropin injection versus synthetic adrenocorticotropic hormone for infantile spasms, JHEOR, 2021, 8(1), 1-9,  [Accessed on 22nd August 2023] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839629/pdf/jheor_2021_8_1_18727.
3. Mallinckrodt ARD Inc, US Food and Drug Administration [Revised on 4/2018] [Accessed on 23rd August 2023],   https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/008372s057lbl.pdf
4. KD Tripathi, Anterior Pituitary Hormones, Essentials of Medical Pharmacology, 8th Edition, 2019, 257-266.